The Cross-Validated Adaptive Signature Design
暂无分享,去创建一个
[1] F. Balis,et al. Evolution of anticancer drug discovery and the role of cell-based screening. , 2002, Journal of the National Cancer Institute.
[2] R. Schilsky. End points in cancer clinical trials and the drug approval process. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] Mace L. Rothenberg,et al. Improving the evaluation of new cancer treatments: challenges and opportunities , 2003, Nature Reviews Cancer.
[4] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[5] E. Wit. Design and Analysis of DNA Microarray Investigations , 2004, Human Genomics.
[6] Leo Breiman,et al. Bagging Predictors , 1996, Machine Learning.
[7] R. Simon,et al. Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients , 2005, Clinical Cancer Research.
[8] Annette M. Molinaro,et al. Prediction error estimation: a comparison of resampling methods , 2005, Bioinform..
[9] Richard Simon,et al. Bias in error estimation when using cross-validation for model selection , 2006, BMC Bioinformatics.
[10] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[11] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .
[12] J. Nevins,et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. , 2007, The Lancet. Oncology.
[13] S. Küçücük,et al. Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer , 2008, Cancer investigation.
[14] Antje Hoering,et al. Randomized Phase III Clinical Trial Designs for Targeted Agents , 2008, Clinical Cancer Research.